[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:fallopian-tube-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":313,"states":357},"Fallopian Tube Carcinoma",121,111,[8,16,23,30,37,43,49,55,61,67,73,79,85,91,97,103,109,115,122,128,134,140,145,151,157,163,169,175,181,187,193,199,205,211,217,223,229,235,241,248,254,260,266,272,277,283,289,295,301,307],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07318558","A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)",[12],"Phase 3","RECRUITING","2026-08-26T02:19:14.560989Z","2026-07-24T01:27:14.897512Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07322094","CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer",[20],"Phase 1\u002FPhase 2","2026-08-26T02:15:23.202838Z","2026-07-19T19:36:05.068641Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06682988","A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine",[27],"Phase 2","2026-08-26T02:16:26.411851Z","2026-07-05T05:32:16.766886Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT06930755","Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer",[34],"Phase 1","2026-08-26T02:18:19.586423Z","2026-07-05T05:32:16.707225Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT06843447","A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)",[20],"2026-08-26T02:15:15.642947Z","2026-07-05T05:32:16.697930Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06803680","A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors",[34],"2026-08-26T02:16:46.951087Z","2026-07-05T05:32:16.694406Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT07059845","A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer",[27],"2026-08-26T02:15:40.343619Z","2026-06-04T01:30:07.896241Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT07546500","A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression",[12],"2026-08-26T02:16:48.735701Z","2026-05-29T15:36:40.191734Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06639074","Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial",[27],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:29.723942Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06469281","A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers",[34],"2026-08-26T02:17:10.213717Z","2026-05-05T02:43:29.649784Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT04516447","A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer",[34],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:29.538962Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06366490","Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer",[34],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:29.471463Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05538091","Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",[27],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:29.380981Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05887609","An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib",[27],"2026-08-26T02:19:16.454910Z","2026-05-05T02:43:29.336719Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06580314","Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer",[12],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:29.331227Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT07218809","AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer",[12],"2026-08-26T02:16:23.080181Z","2026-05-05T02:43:29.327362Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06617923","Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer",[27],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:29.295095Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":120,"content_modified":121},"NCT06161025","A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[119],"Phase 2\u002FPhase 3","2026-08-26T02:17:18.747857Z","2026-05-05T02:43:29.195828Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT05610735","Combination Therapy for Recurrent Ovarian Cancer",[20],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:29.195795Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT06888921","A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer",[20],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:29.182828Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT05920798","Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",[20],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:29.054306Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":138,"content_modified":144},"NCT05231122","Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer",[27],"2026-05-05T02:43:29.046114Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":120,"content_modified":150},"NCT05080946","Using Aspirin to Improve Immunological Features of Ovarian Tumors",[149],"Early Phase 1","2026-05-05T02:43:29.041300Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT06915025","Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w\u002F Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w\u002F Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer",[12],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:28.985522Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT07214779","Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression",[12],"2026-08-26T02:19:08.084946Z","2026-05-05T02:43:28.882083Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT05942300","CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer",[34],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:28.855543Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT06890338","A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",[27],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.627515Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT06787612","Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer",[27],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:28.507434Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT06483048","MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer",[34],"2026-08-26T02:19:05.360997Z","2026-05-05T02:43:28.503673Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT05415709","Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer",[149],"2026-08-03T02:06:20.225302Z","2026-05-05T02:43:28.502526Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT06305299","Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells",[34],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:28.485998Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT06856499","Cirtuvivint\u002FOlaparib in Breast Cancer Susceptibility Gene\u002FHomologous Recombination Deficiency Platinum Resistant Ovarian Cancer",[34],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:28.484898Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT05739981","Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[20],"2026-08-26T02:15:42.447052Z","2026-05-05T02:43:28.399515Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT04590326","A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab",[20],"2026-08-26T02:18:38.865010Z","2026-05-05T02:43:28.360231Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT03878849","Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer",[27],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:28.317727Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT04055649","ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer",[27],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:28.316450Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT06690775","CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.",[27],"2026-08-26T02:19:03.581490Z","2026-05-05T02:43:28.216661Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT05281471","Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant\u002FRefractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)",[12],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:28.112777Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":246,"content_modified":247},"NCT06412120","Study Evaluating Safety, Tolerability, and Metabolism of Niraparib",[245],"Phase 4","2026-08-26T02:19:18.331180Z","2026-05-05T02:43:27.997904Z",{"nct_id":249,"title":250,"phases":251,"status":13,"updated_at":252,"content_modified":253},"NCT07151391","The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)",[27],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.826884Z",{"nct_id":255,"title":256,"phases":257,"status":13,"updated_at":258,"content_modified":259},"NCT02637934","Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET\u002FCT",[34],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.812215Z",{"nct_id":261,"title":262,"phases":263,"status":13,"updated_at":264,"content_modified":265},"NCT06290193","Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery",[27],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:27.758747Z",{"nct_id":267,"title":268,"phases":269,"status":13,"updated_at":270,"content_modified":271},"NCT05659381","Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer",[12],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:27.677486Z",{"nct_id":273,"title":274,"phases":275,"status":13,"updated_at":120,"content_modified":276},"NCT07226427","A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer",[34],"2026-05-05T02:43:27.657949Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT04919629","APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion",[27],"2026-08-26T02:17:52.450442Z","2026-05-05T02:43:27.623918Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT05983276","Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer",[27],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:27.575641Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":293,"content_modified":294},"NCT04575935","Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial",[12],"2026-08-26T02:19:26.493949Z","2026-05-05T02:43:27.394966Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT05952453","Newly Diagnosed Stage III\u002FIV Ovarian Cancer, Neoadjuvant Carbo\u002FTaxol\u002FPembro, Maintenance Olaparib\u002FPembro",[27],"2026-08-26T02:17:16.980188Z","2026-05-05T02:43:27.281937Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT04606914","Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[27],"2026-08-26T02:17:32.059863Z","2026-05-05T02:43:27.132670Z",{"nct_id":308,"title":309,"phases":310,"status":13,"updated_at":311,"content_modified":312},"NCT06315491","A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer",[27],"2026-08-03T01:57:36.164517Z","2026-05-05T02:43:26.900983Z",[314,318,321,325,328,332,335,339,342,345,348,351,354],{"biomarker":315,"count":316,"slug":317},"BRCA1 Gene",6,"brca1-gene",{"biomarker":319,"count":316,"slug":320},"Folate Receptor Alpha","folate-receptor-alpha",{"biomarker":322,"count":323,"slug":324},"BRCA Gene Family",5,"brca-gene-family",{"biomarker":326,"count":323,"slug":327},"G1\u002FS-Specific Cyclin-E1","g1-s-specific-cyclin-e1",{"biomarker":329,"count":330,"slug":331},"BRCA2 Gene",4,"brca2-gene",{"biomarker":333,"count":330,"slug":334},"FRα","fr",{"biomarker":336,"count":337,"slug":338},"CLDN6 Gene",3,"cldn6-gene",{"biomarker":340,"count":337,"slug":341},"MRC1 wt Allele","mrc1-wt-allele",{"biomarker":343,"count":337,"slug":344},"MSI1 Gene","msi1-gene",{"biomarker":346,"count":337,"slug":347},"MUC16 wt Allele","muc16-wt-allele",{"biomarker":349,"count":337,"slug":350},"RAD51C Gene","rad51c-gene",{"biomarker":352,"count":337,"slug":353},"RAD51D Gene","rad51d-gene",{"biomarker":355,"count":337,"slug":356},"TBCE wt Allele","tbce-wt-allele",[358,362,366,370,374,378,382,386,390,393,397,401,405,408,412,415,418,421,425,428,431,435,438,442],{"state":359,"count":360,"slug":361},"Texas",56,"texas",{"state":363,"count":364,"slug":365},"Florida",52,"florida",{"state":367,"count":368,"slug":369},"New York",51,"new-york",{"state":371,"count":372,"slug":373},"Pennsylvania",46,"pennsylvania",{"state":375,"count":376,"slug":377},"California",43,"california",{"state":379,"count":380,"slug":381},"Ohio",40,"ohio",{"state":383,"count":384,"slug":385},"Massachusetts",33,"massachusetts",{"state":387,"count":388,"slug":389},"Minnesota",32,"minnesota",{"state":391,"count":388,"slug":392},"Virginia","virginia",{"state":394,"count":395,"slug":396},"North Carolina",28,"north-carolina",{"state":398,"count":399,"slug":400},"New Jersey",27,"new-jersey",{"state":402,"count":403,"slug":404},"Tennessee",26,"tennessee",{"state":406,"count":403,"slug":407},"Washington","washington",{"state":409,"count":410,"slug":411},"Illinois",24,"illinois",{"state":413,"count":410,"slug":414},"Michigan","michigan",{"state":416,"count":410,"slug":417},"Missouri","missouri",{"state":419,"count":410,"slug":420},"Oregon","oregon",{"state":422,"count":423,"slug":424},"Arizona",21,"arizona",{"state":426,"count":423,"slug":427},"Maryland","maryland",{"state":429,"count":423,"slug":430},"Oklahoma","oklahoma",{"state":432,"count":433,"slug":434},"Georgia",19,"georgia",{"state":436,"count":433,"slug":437},"Louisiana","louisiana",{"state":439,"count":440,"slug":441},"Alabama",18,"alabama",{"state":443,"count":440,"slug":444},"Kentucky","kentucky"]